Skip to content

Biohaven BHVN Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

ADMA Biologics logo
ADMA BiologicsADMA
0
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Biohaven's convertible preferred stock outstanding shares?
Biohaven (BHVN) reported convertible preferred stock outstanding shares of 0 in Q1 2026.